12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-suspension Delivery Technology in Patients with COPD

GT Ferguson; KF Rabe; E Bourne; S Ballal; K DeAngelis; M Aurivillius; C Reisner; P Dorinsky

doi:10.1055/s-0039-3403158

Pneumologie, Inhaltsverzeichnis

Pneumologie 2020; 74(S 01): 43-44
DOI: 10.1055/s-0039-3403158

Posterbegehung (PO08) – Sektion Klinische Pneumologie

Klinische Studien bei COPD und Asthma

Georg Thieme Verlag KG Stuttgart · New York

12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-suspension Delivery Technology in Patients with COPD

GT Ferguson

¹Pulmonary Research Institute of Southeast Michigan

,

KF Rabe

²Zentrum für Pneumologie Und Thoraxchirurgie, Lungenclinic Grosshansdorf GmbH; Airway Research Center North (Arcn), Deutsches Zentrum für Lungenforschung (Dzl)

,

E Bourne

³Pearl Astrazeneca

,

S Ballal

³Pearl Astrazeneca

,

K DeAngelis

³Pearl Astrazeneca

,

M Aurivillius

⁴Astrazeneca

,

C Reisner

⁴Astrazeneca

,

P Dorinsky

³Pearl Astrazeneca

› Institutsangaben